CHICAGO — Ron Peck, MD, senior vice president of clinical research at Tesaro, spoke with HemOnc Today at ASCO Annual meeting about several agents in the company’s oncology pipeline.
Research presented at ASCO explored use of the PARP inhibitor niraparib (MK-4827, Tesaro) in combination with the anti-PD-1 agent pembrolizumab (Keytruda, Merck) for patients with triple-negative breast cancer or platinum-resistant ovarian cancer.
The company also presented data from the QUADRA study, a phase 2, open-label, single-arm study that assessed daily niraparib therapy for women with heavily pretreated ovarian cancer. Most study participants had BRCA wild-type disease.
Another trial is assessing niraparib alone as maintenance therapy for women with ovarian cancer who completed front-line chemotherapy.
“That [study] will generate data somewhere in the early part of 2020,” Peck told HemOnc Today.
Tesaro also is evaluating combinations of agents within its pipeline for treatment of multiple diseases, including ovarian, endometrial and lung cancers.